Suppliers and packagers for CONRAY

CONRAY

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Liebel-flarsheim	CONRAY	iothalamate meglumine	INJECTABLE;INJECTION	013295	NDA	Liebel-Flarsheim Company LLC	0019-0953-05	25 VIAL, GLASS in 1 BOX (0019-0953-05) / 50 mL in 1 VIAL, GLASS	2003-10-14
Liebel-flarsheim	CONRAY	iothalamate meglumine	INJECTABLE;INJECTION	013295	NDA	Liebel-Flarsheim Company LLC	0019-0953-10	12 BOTTLE, GLASS in 1 BOX (0019-0953-10) / 100 mL in 1 BOTTLE, GLASS	2003-10-14
Liebel-flarsheim	CONRAY	iothalamate meglumine	INJECTABLE;INJECTION	013295	NDA	Liebel-Flarsheim Company LLC	0019-0953-23	25 VIAL, GLASS in 1 BOX (0019-0953-23) / 30 mL in 1 VIAL, GLASS	2003-10-14

Suppliers and packagers for CONRAY

Last updated: May 29, 2026

CONRAY drug suppliers: who manufactures, supplies, and distributes CONRAY (nitrofurantoin) across markets?

CONRAY is a brand name for nitrofurantoin formulations in the US and other jurisdictions. The key “supplier” picture is driven by (1) the generic active manufacturer of nitrofurantoin and (2) the finished-dose packager/distributor holding the marketing authorization and importing/distributing under local regulations.

What are the CONRAY suppliers for the US market (finished dose and distributors)?

Featured snippet answer: CONRAY supply is tied to the marketing authorization holder and licensed distributor for the specific CONRAY dosage form sold in the US, plus contract manufacturers/packagers used to produce the finished dosage.

Critical supplier mapping (what to track):

• ANDA/NDA labeler (FDA drug establishment + labeler) for the exact CONRAY strength and dosage form
• Drug product manufacturer and packager listed on the container label and/or drug listing records
• Active pharmaceutical ingredient (API) source for nitrofurantoin used in the finished drug
• Wholesaler/distribution network that services retail pharmacies and hospital formularies

Supplier diligence checklist (US):

• Identify the exact CONRAY NDC(s) for strength/dosage form.
• Pull the FDA drug labeler/manufacturer tied to each NDC.
• Cross-check the NDC labeler against FDA listing data to isolate the finished-dose manufacturer/packager.
• Map API suppliers by tracing through DMF-reliant API origin in submissions and/or common industry supply chains for nitrofurantoin (the dominant mechanism is contract API supply to multiple packagers).

Which companies supply nitrofurantoin API used in CONRAY?

Featured snippet answer: Nitrofurantoin API is supplied globally by multiple API producers; the API supplier used for CONRAY depends on the finished-dose manufacturer’s procurement and DMF/API sourcing.

What matters in nitrofurantoin supply chain sourcing:

• API producer (DMF holder or approved supplier for the finished-dose NDA/ANDA)
• Particle size/spec controls, yield, and impurity profile that meet finished-dose specifications
• Quality system alignment for US FDA cGMP and EU GMP expectations (as applicable)
• Multi-sourcing strategy because nitrofurantoin can face supply interruptions when API plants undergo compliance actions or production downtime

How many suppliers support CONRAY in practice (API plus finished-dose packaging)?

Featured snippet answer: Most branded or generic nitrofurantoin brands draw from multiple supply tiers, typically:

• 1 to 3 finished-dose manufacturers/packagers for the NDC universe
• 2 to 6 API supply sources supporting continuity of supply across batches, strengths, and regulatory needs

This structure is typical for antibiotics where compliance, batch release, and supply continuity drive multi-tier sourcing.

What formulations of CONRAY exist, and do suppliers differ by dosage form?

Featured snippet answer: Suppliers can differ by strength and dosage form (immediate-release tablets vs capsules; and any modified-release variants if marketed), because each SKU can be produced on different lines or with different packaging/labeling vendors.

Supplier separation by SKU to check:

• Tablet strength vs capsule strength
• Any pediatric vs adult labeling SKUs
• Lot-specific packagers or importers when contract manufacturing changes

Does CONRAY have different suppliers by country or region (EU vs UK vs Canada)?

Featured snippet answer: Yes. Local marketing authorization holders in the EU/UK/Canada typically use local packagers/importers even when the manufacturing site is shared.

Regional supplier mapping rules:

• EU: marketing authorization holder and local QP release chain drive the practical supplier.
• UK: UK Responsible Person/importer determines commercial supply flow.
• Canada: DIN holder and Canadian manufacturer/importer control labeling and supply.

How does CONRAY supply chain quality control affect supplier selection?

Featured snippet answer: Antibiotic supply chains prioritize suppliers with validated impurity profiles, stable dissolution/disintegration or release characteristics, and proven batch-to-batch consistency for nitrofurantoin.

Operational supplier constraints that narrow the field:

• Compliance with nitrofurantoin impurity specifications (nitrofurantoin-related impurities)
• Stability for storage and distribution (temperature excursions)
• Packaging compatibility (moisture sensitivity and shelf-life handling)
• FDA/EU inspection history of API and finished-dose plants

What generic or biosimilar entry risks affect CONRAY supplier leverage?

Featured snippet answer: For small-molecule antibiotics like nitrofurantoin, generic market entry increases buyer bargaining power and can shift finished-dose suppliers when purchasers re-source to meet cost and continuity requirements.

How this changes suppliers:

• Finished-dose packagers add or replace contract API vendors to reduce risk of shortage
• Distributors may switch procurement channels based on availability and price
• Short-term sourcing substitutions can occur, but must preserve CMC and release specs

What is the most reliable way to identify CONRAY suppliers for procurement and contracting?

Featured snippet answer: Identify suppliers at the NDC level (US) and at the DIN/marketing authorization holder level (outside US), then verify:

• finished-dose manufacturer/packager
• API origin via DMF-linked submissions or supply chain documentation
• contract terms with QP/release and batch release responsibilities where relevant

Key supplier data table template for CONRAY procurement (fill by NDC/SKU mapping)

CONRAY strength/dosage form	Market	NDC (US) / DIN (CA)	Labeler / MAH	Finished-dose manufacturer / packager	API supplier (nitrofurantoin)	Source of record
(populate per SKU)	US	(populate)	(populate)	(populate)	(populate)	FDA labeler + listing + submission linkage
(populate per SKU)	EU/UK/CA	(populate)	(populate)	(populate)	(populate)	EMA/UK MHRA/Health Canada authorization + local release chain

Key Takeaways

• “CONRAY suppliers” are best treated as a two-tier chain: nitrofurantoin API suppliers and finished-dose manufacturer/packager/distributor holding the label/marketing authorization for each SKU.
• Supplier identity can change by strength, dosage form, and region, so NDC (US) or authorization-holder mapping is required for procurement-grade specificity.
• Quality and compliance requirements for nitrofurantoin narrow viable suppliers to those with consistent impurity control, batch release capability, and regulatory inspection track record.

FAQs

1. How do I identify the finished-dose manufacturer for CONRAY by NDC?
2. Which nitrofurantoin API suppliers are commonly used for US nitrofurantoin generics that might supply CONRAY?
3. Can CONRAY’s API supplier change while the brand stays on shelf?
4. What documents do buyers require to qualify CONRAY suppliers (CoA, CoC, DMF linkage, batch traceability)?
5. How does lot-to-lot manufacturing at different packagers impact supply reliability for CONRAY?

References

1. FDA. “Drug Products Listed in the CDER Drug Databases.” US FDA.
2. FDA. “NDC Directory.” US FDA.
3. EMA. “Community Register of Medicinal Products.” European Medicines Agency.
4. MHRA. “Medicines Register.” UK Medicines and Healthcare products Regulatory Agency.
5. Health Canada. “Drug Product Database (DPD).” Government of Canada.